Guest Editors
Dr. Denggang Fu
Email: fdgszxy@163.com
Affiliation: College of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA
Research Interests: leukemia, cancer immunity, immunotherapy, graft-versus-host disease; stem cells, cancer bioinformatics.
Dr. Jinghui Sun
Email: sunji@musc.edu
Affiliation: College of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA
Research Interests: cellular Biomechanics, tumor Immunity, cancer stem, cellsTumor, metastasis, tissue repair
Summary
Recent advancements in cancer research have significantly advanced our understanding of the intricate molecular mechanisms driving cancer progression, leading to the identification of new drug targets and therapeutic strategies. The elucidation of complex signaling pathways and genetic aberrations associated with tumorigenesis has provided valuable insights into potential targets for intervention. Additionally, a paradigm shift towards revolutionary approaches such as targeted therapies, immune checkpoint inhibitors (e.g., PD-1-based immunotherapy), and adoptive cell therapies like CAR-T cell therapy has reshaped the landscape of anticancer treatment.
However, the efficacy of these treatments can vary among individuals, highlighting the need to explore cancer-specific vulnerabilities, overcome drug resistance mechanisms, and identify new druggable targets. To address these challenges, cutting-edge technologies such as multi-omics approaches, pharmacogenomics, and pharmacogenetics are being employed to comprehensively characterize the molecular profiles of tumors. These integrative approaches facilitate the identification of key molecular alterations driving tumorigenesis and inform the development of personalized therapeutic strategies.
This ongoing progress underscores the importance of interdisciplinary collaboration and translational research efforts aimed at advancing our understanding of cancer biology and translating scientific discoveries into innovative therapies for improved patient outcomes. Additionally, please note that manuscripts based solely on bioinformatics, computational analysis, or predictions from public databases—without validation through independent cohorts, patient cohorts, or biological validation (in vitro or in vivo)—are not suitable for publication in this journal.
This study includes but is not limited to the following research topics:
1) Elaborating on novel drug candidates, whether natural, synthetic, or of biological origin, offers diverse avenues for cancer therapy
2) Repositioning existing therapeutic agents with novel drug targets
3) Identification of critical markers modulating important biological processes in cancer development or outcomes
4) Pharmacology research, including basic and translational studies, clinical trials, bioinformatics, and machine learning, informs drug development strategies based on tumor biomarkers
5) Exploring the pharmacological mechanisms of drug therapy for various tumors
Keywords
cancer, molecular targets, molecular modeling, pharmaceutical discovery, computational drug design, multi-omics, immunotherapy, drug response
Login
Register
Submit a Paper
Propose a Special lssue
